Matsas and V. Coordinated by R. Matsas; Participants: C. Zurzolo, PM Lledo and F. Lazarini IP-Paris. Matsas; Participants: D.
Bohl IP-Paris, R. Grailhe IP-Korea. Fondation BNP Paribas Use of human stem cells for the treatment of neurodegenerative diseases and injuries of the brain and spinal cord. Wings for Life Foundation for Spinal Cord Research Therapeutic potential of Schwann cells genetically engineered to express PSA after transplantation in the lesioned mouse spinal cord. Greek General Secretariat for Research and Technology Development of infrastructure in cutting-edge technologies for innovative diagnostic and therapeutic strategies. Application of the neuroprotective factor IGF1 for the treatment of brain trauma and neurodegeneration F.
Stylianopoulou — coordinator. Role of calcium mobilization in neuronal differentiation: novel aspects of single cell and organellar calcium signals. Prodromidou, I. Vlachos, M. Gaitanou, G. Kouroupi, A. Hatzigeorgiou, R.
The Laboratory of Cellular and Molecular Neurobiology has a track record in educational and training activities. In conjunction with the Biology Departments of the University of Athens and the University of Patras as well as the Medical School of the University of Athens, a large number of graduate students have performed their thesis towards an MSc or PhD degree. The researchers of the lab are actively involved in teaching in University post-graduate courses while they undertake undergraduate and post-graduate students for training and theses. Communicating science to the public is an important task of our lab.
Here are some examples of open-to-the-public actions that we have participated in:. Neurochem Res. Front Cell Neurosci. Stem Cells International, in Press. Synaptic dysfunction in neurodegenerative and neurodevelopmental diseases: an overview of induced pluripotent stem cell-based disease models. PLOS Genet. Stem Cell Reports 5 3 Mol Ther 23 6 Papastefanaki F, Matsas R. GLIA 63 7 Stem Cells 32 6 Stylianopoulou Subventricular zone-derived neural stem cell grafts protect against hippocampal degeneration and restore cognitive function in the mouse following intrahippocampal kainic acid administration.
Stem Cells Transl Med. PLoS One. Neural stem cells transplanted in a mouse model of Parkinson'sdisease differentiate to neuronal phenotypes and reduce rotational deficit. Curr Gene Ther. Apr;11 2 Stem Cells Exp Neurol J Neurochem. Dec; 5 Oct; 2 Mol Cell Neurosci, — Lavdas A and Matsas R Squire, Editor Oxford: Academic Press, pp Neuropharmacology, FEBS Lett. Cell Cycle. Mar 15;7 6 J Biol Chem. Curr Med Chem. Brain Gene Expr Patterns GLIA 53 8 J Virol. Microsurgery Eur J Neurosci.
Neuronal and glial apoptosis in human traumatic brain injury. Our analysis suggests that the focus of neuroprotection research needs to shift from protecting dying and injured neurons at acute time points to modulating the aberrant glial response in sub-acute and chronic time points. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Immunomodulatory therapies for TBI need to be developed with a goal to guide inflammation toward the reparative phenotype 99 , However, this can result in some functions no longer being available.
Biochem J. Brain Res Mol Brain Res. Int J Dev Neurosci. Author s : Igor M. Author s : Selmani, A. Author s : Rivera, Francisco J. Published in: Frontiers Media S. Frontiers in Cell and Developmental Biology Published in: Elsevier Heliyon, Vol 4, Iss 2 Frontiers in Neuroscience Author s : Unger, M. Published in: Springer Nature Molecular Neurobiology Front Cell Neurosci.
Although many modern day therapies focus on synthetic and na- ral medicinal Contemporary Neuroscience Cell Therapy, Stem Cells and Brain Repair. Exogenous stem cells. The application of exogenous cell therapy in neurology began with neurodegenerative diseases, for which fetal ventral.
Supplementary material. Appendix 1. Cell-based therapeutic strategies for multiple sclerosis Neil J Scolding. Oxford Academic. Google Scholar.
Marcelo Pasquini. Stephen C Reingold. Jeffrey A Cohen. Cite Citation. Permissions Icon Permissions. Abstract The availability of multiple disease-modifying medications with regulatory approval to treat multiple sclerosis illustrates the substantial progress made in therapy of the disease. Table 1. Table 2. Box 3 Key issues related to future trials of MSC transplantation in multiple sclerosis.
Box 4 Key issues related to future trials of OPC transplantation in multiple sclerosis. Box 5 Ethical issues related to cell-based therapies. Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL producing mucosal-associated invariant T cells in multiple sclerosis. Search ADS. Remyelination of the spinal cord following intravenous delivery of bone marrow cells.
Immunoablation and autologous haematopoietic stem-cell transplanatation for agressive multiple sclerosis: a multicentre single-group phase 2 trial. Autoimmune Disease Working Party. Hepatocyte growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis models. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis.
Remyelination of CNS axons by Schwann cells transplanted from the sciatic nerve. Autologous mesenchymal stem cell therapy in progressive multiple sclerosis: an open label study. Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. Association of nonmyeloablative hematopoietic stem cell transplantation with neurologic disability in patients with relapsing-remitting multiple sclerosis.
Autologous hematopoietic stem cell transplantation for multiple sclerosis - if confused or hesitant, remember: treat with standard immune suppressive drugs and if no inflammation, no response. Safety and efficacy of opicinumab in acute optic neuritis RENEW : a randomised, placebo-controlled, phase 2 trial. Center for International Blood and Marrow Research. Cortical remyelination: a new target for repair strategies in multiple sclerosis. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats.
Cryopreserved mesenchymal stromal cells are susceptible to T-cell mediated apoptosis which is partly rescued by IFNgamma licensing. Actin cytoskeletal disruption following cryopreservation alters the biodistribution of human mesenchymal stromal cells in vivo. Bone marrow transdifferentiation in brain after transplantation: a retrospective study. Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.
Disability outcome measures in multiple sclerosis trials: current status and future prospects. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Da Silva Meirelles. Mesenchymal stem cells reside in virtually all post-natal organs and tissues.
Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: implications for MS. Diminished Th17 not Th1 responses underlie multiple sclerosis abrogation after hematopoietic stem cell transplantation. Bone marrow mesenchymal stromal cells isolated from multiple sclerosis patients have distinct gene expression profile and decreased suppressive function compared with healthy counterparts.
Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Minimal criteria for defining multipotent mesenchymal stromal cells. Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation. Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-gamma licensing. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group.
Is it time to target no evident disease activity NEDA in multiple sclerosis? Glial progenitor cell-baed treatment and modeling of neurological disease. Human mesenchymal stem cells infiltrate the spinal cord, reduce demyelination, and localize to white matter lesions in experimetnal autoimmune encephalomyelitis.
Positive phase II double-blind randomized placebo-controlled crossover trial of clemastine fumarate for remyelination of chronic optic neuropathy in MS ES1. Immune-modifying agents do not impair the survival, migration or proliferation of oligodendrocyte progenitors CG-4 in vitro. Characterization of autologous mesenchymal stem cell-derived neural progenitors as a feasible source of stem cells for central nervous system applications in multiple sclerosis. The cost of multiple sclerosis drugs in the US and pharmaceutical industry: too big to fail?
Advances in and algorithms for the treatment of relapsing-remitting multiple sclerosis. International Society for Stem Cell Research. Extensive fusion of haematopoietic cells with Purkinje neurons in response to chronic inflammation. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Safety and immunologic effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis.
Purkinje cell fusion and binucleate heterokaryon formation in multiple sclerosis cerebellum. Mesenchymal stemm cell-secreted superoxide dismutase promotes cerebellar neuronal survival. Possible induction of acute disseminated encephalomyelitis ADEM -like demyelinating illness by intrathecal mesenchymal stem cell injection. Safety of cell therapy with mesenchymal stromal cells SafeCell : a systematic review and meta-analysis of clinical trials.
Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG Comparative analysis of human mesenchyal stem cells from bone marrow and adipose tissue under xeno-free conditions for cell therapy. The potential of human umbilical cord-derived mesenchymal stem cells as a novel cellular therapy for multiple sclerosis.
Gliosis and brain remodeling after treatment of stroke in rats with marrow stromal cells. Allogeneic mesenchymal stem cells transplantation in treatment of multiple sclerosis. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis.
Human placenta-derived cells PDA for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study. Characterization of in vitro expanded bone marrow-derived mesenchymal stem cells from patients with multiple sclerosis. Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience.
A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview. Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: Implications for assessment of disease activity and treatment. Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation.
The therapeutic effect of mesenchymal stem cell trnasplantation in experimental autoimmune encephalomyelitis is mediated by peripheral and central mechanisms. Resetting autoimmunity in the nervous system: the role of hematopoietic stem cell transplantation. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients.
Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis. T cell repertoire following autologous stem cell transplantation for multiple sclerosis. Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo.
High-dose immunosuppressive therpay and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis HALT-MS. Nature Editorial. FDA should stand firm on stem-cell treatments. US regulators must regain the upper hand in the approval system. New York Times. Transplantation of mesenchymal stem cells in multiple sclerosis [in Russian].
Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor. Normal bone marrow hematopoietic stem cell reserves and normal stromal cell function support the use of autologous stem cell transplantation in patients with multiple sclerosis. Sustained improvement in expanded disability status scale as a new efficacy measure of neurologic change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis.
Functional heterogeneity of mesenchymal stem cells: implications for cell therapy. Induction of neurotrophin expression via human adult mesenchymal stem cells: implications for cell therapy in neurodegenerative diseases. Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. Alterations in the secretome of MSCs isolated from patients with MS are in keeping with their reduced neuroprotective potential under conditins of oxidative stress P Cell Therapy for multiple sclerosis: an evolving concept with implications for other neurodegenerative diseases.
Safety and feasibility of autologous bone marrow cellular therapy in relapsing-progressive multiple sclerosis. Adult human mesenchymal cells proliferate and migrate in response to chemokines expressed in demyelination. Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.
Human mesenchymal stem cells impact Th17 and Th1 responses through a prostaglandin E2 and myeloid-dependent mechanism. A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper.
Reduced expression of mitochondrial fumarate hydratase contributes to impaired MSC-mediated neuroprotection in multiple sclerosis Google Preview. Transplantation of an acutely isolated bone marow fraction repairs demyelinated adult rat spinal cord axons. Endogenous tissue plasminogen activator mediates bone marrow strom cell-induced neurite remodeling after stroke in mice. Therapeutic advances and future prospects in progressive forms of multiple sclerosis.
CDa identifies a population of highly myelinogenic, migration-competent and efficiently engrafting human oligodendrocyte progenitor cells. Soelberg Sorensen. Haematopoietic stem cell transplants should be a second-line therapy for highly active MS - No. NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs. Autologous haematopoietic stem cell transplantation in multiple sclerosis: a meta-analysis P Prospective validation of the predictive power of the Hematopoietic Cell Transplantation Comorbidity Index: a center for international blood and marrow transplant research study.
Hematopoietic cell transplantation HCT -specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. Survival and functionality of human induced pluripotent stem cell-derived oligodendrocytes in a nonhuman primate model for multiple sclerosis.
Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. Long-term evolution of multiple sclerosis disability in the treatment era. Analysis of tissues following mesenchymal stromal cell therapy in humans indicate limited long-term engraftment and no ectopic tissue formation.
Fetal and adult human oligodendrocyte progenitor cell isolates myelinate the congenitally dysmyelinated brain. Neonatal chimerization with human glial progenitor cells can both remyelinate and rescue the otherwise lethally hypomyelinated shiverer mouse. World Medical Association Declaration of Helsinki. Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study. Bone marrow stromal cells reduce axonal loss in experimental autoimmune encephalomyelitis mice. For commercial re-use, please contact journals. Issue Section:.
Download all figures. Supplementary data. Supplementary Material. View Metrics. Email alerts New issue alert. Advance article alerts. Article activity alert. Subject alert. Receive exclusive offers and updates from Oxford Academic.
Related articles in PubMed Prolactin hormone exerts anti-tumorigenic effects in HER-2 overexpressing breast cancer cells through regulation of stemness. Hepatitis E virus in hematopoietic stem cell transplant recipients: A systematic review. Synthetic probes for in vitro purification and in vivo tracking of hepatocytes derived from human pluripotent stem cells.